Shingles Vaccine

“Merck & Co Inc. filed a Biologics License Application (BLA) with the FDA on April 25 for ZOSTAVAX to reduce the risk of shingles and postherpetic neuralgia, the persistent, often debilitating long-term nerve pain that is the most common complication of shingles; and to reduce the total burden of pain and discomfort caused by shingles”, Merck stated in a press release.



✓ Join 150,000+ subscribers
✓ Get KevinMD's most popular stories